Please login to the form below

Not currently logged in

BMS plans major expansion of Orencia plant

Will invest $250m in biologics manufacturing facility

BMS plans major expansion of Orencia plant

Bristol-Myers Squibb (BMS) has said it plans to invest around $250m in an expansion of its biologics manufacturing facility in Devens, Massachusetts, that will almost double the site's workforce.

Devens manufactures bulk biologic drugs and is the main site for the production of BMS' fast-growing rheumatoid arthritis treatment Orencia (abatacept), and currently employs around 400 workers.

The expansion will add two new buildings and introduce development and clinical trial manufacturing capabilities to the site while providing employment for approximately 350 additional staff over time.

Construction of around 200,000 square feet of laboratory and office space is due to start later this year – doubling the overall size of the facility – and is set to be completed in 2015.

The announcement consolidates Devens at the heart of BMS' biologics production network. BMS already operates a bulk production facility in Syracuse, New York, and carries out finishing and packaging activities at a plant in Manati, Puerto Rico, whilst also relying on contract manufacturing organisations (CMOs).

BMS said it will begin moving some biologics process development functions closer to Devens during construction, making use of 30,000 square feet of leased lab space in Hopkinton that will be retained after the expansion is finished.

"This initiative is designed to accelerate the development of new biologics medicines through the closer alignment of biologics research and development, and manufacturing," commented Lou Schmukler, BMS' president of global manufacturing and supply.

"Biologics are increasingly important in the treatment of serious diseases and are a growing part of our company's pipeline of potential new therapies," he added. BMS' late-stage pipeline includes nivolumab in multiple phase III trials for lung and renal cancer as well as melanoma, and elotuzumab which has now reached the pivotal trials stage in multiple myeloma.

The Devens site was completed in 2009 and represented the largest capital investment in BMS' history, with a price tag of $750m.

12th April 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...